Deutsche Bank Lowers Price Target on CME Group (CME) to $390
More News related to CME
- CME Group to Launch 26 New Monthly PJM Electricity Futures Contracts on ClearPort
- CME Group Announces Thanksgiving Day Holiday Hours
- CME Group Names Michael O'Connell as Managing Director, Clearing Business Development
- CME Group to Host a Four-Part Online Series for Careers in the Futures Industry
- CME Group to List Electronic Feeder Cattle Options
More News related to Analyst Comments
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
Deutsche Bank lowered their price target on CME Group (NYSE: CME) from $435 to $390, following the merger with NYMEX. The firm said given the tough comparables and dilutions, they are maintaining their Hold rating.
DB noted that the acquisition expands CME's commodities derivatives exposure as well as adding an OTC clearing capability.
Related Categories
Analyst CommentsStocks Mentioned
+19.23Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
